At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 74 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Alfuzosin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Double Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of Alfuzosin in Treating Men With ED and Mild LUTS.
In Brief
A Phase 3 clinical trial evaluating Placebo and Alfuzosin for Erectile Dysfunction and Lower Urinary Tract Symptoms. Completed, enrolled 74 participants across 4 sites.
Detailed Summary
The purpose of this study is to assess the effect of Alfuzosin in treating Erectile Dysfunction in men with mild lower urinary tract symptoms based upon a change from baseline in erectile function (EF) domain of International Index of Erectile Function (IIEF).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErectile Dysfunction, Lower Urinary Tract Symptoms
CountriesUnited States
CollaboratorsSanofi
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartJun 2009
Primary CompletionOct 2012
TodayJul 2026
First PostedMay 5, 2009
Enrollment StartJun 1, 2009
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 17.2 years ago
Interventions
Placebodrug
Alfuzosin-matched One tablet once daily
Alfuzosindrug
10 mg once daily